J&J Stock Price May Be Pricing In Unrealistic Growth Expectations

Johnson & Johnson (JNJ) has been a standout performer in the market, with its stock price up 56.5% over the past twelve months. However, analysts at Trefis suggest that the current stock price may be pricing in growth that is not reflected in the company's near-term guidance.

According to their valuation model, justifying today's price of $271.19 over a three-year horizon implies revenue growth of roughly 11.9% a year, even after factoring in significant margin expansion. However, management has guided full-year 2026 reported sales growth of only 7.0% to 7.6%, which is well below the required 12% annualized growth over the next three years.

The company's revenue growth has been strong, with a 8.1% year-over-year increase in the last twelve months. However, this growth has come from just one side of the business - the medicines segment, which grew double digits in the second quarter of 2026. The other side, MedTech, posted only a 3.6% operational growth in the same quarter.

The risk for investors is that the company's revenue growth slows down to match its near-term guidance, which would lead to a decrease in the stock price multiple. This scenario seems likely, as the implied volatility on the stock at 22 sits in the 69th percentile of its own past year.